Trial Profile
A retrospective study assessing efficacy of Rituxan® in patients with Immune thrombocytopenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 10 Jan 2017 New trial record
- 06 Dec 2016 Results (n=233) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.